Implications of Biomarker Testing in the Era of Targeted NSCLC Therapies
This module will present current and new clinical data of targeted therapies and how this information translates into personalized medicine and the development of individualized treatment plans for patients with NSCLC based on expression of biomarkers.
Implications of Biomarker Testing in the Era of Targeted NSCLC Therapies
This module will present current and new clinical data of targeted therapies and how this information translates into personalized medicine and the development of individualized treatment plans for patients with NSCLC based on expression of biomarkers.
Tissue Acquisition and Analysis

This module will include a review of guidelines, tissue acquisition and sample preparation, differentiating assays, specific biomarker types and subtypes, molecular and cytopathology evaluation, and tips on how to interpret lab results.

Tissue Acquisition and Analysis

This module will include a review of guidelines, tissue acquisition and sample preparation, differentiating assays, specific biomarker types and subtypes, molecular and cytopathology evaluation, and tips on how to interpret lab results.

Accurate Diagnosis and Personalized Treatment of NSCLC for the Interdisciplinary Team
It is essential that all members of the NSCLC care team understand the necessary processes and are equipped to apply current research on genomic targets to testing for mutations/drivers in appropriate advanced NSCLC patients.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2021
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.
Recorded Presentation from the NCCN Pharmacy Updates: Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
Many new options exist for the treatment of advanced non-small cell lung cancer (NSCLC) in addition to traditional platinum-based chemotherapy. Pharmacists should be aware of the new data and recommendations for immunotherapies and targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies; therefore, pharmacists should educate patients about the possibility of adverse events and the need to report symptoms to their health care teams to avoid severe complications.
Use of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Real-World Issues

Cancer immunotherapy is a rapidly growing and dynamic field, particularly for diseases such as lung cancer where immune checkpoint inhibitors are an important component of treatment.

Pages

Subscribe to RSS - Lung Cancers